Terms: = Breast cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Treatment
132 results:
1. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
2. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
3. Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation.
Sinha S; Paul S; Acharya SS; Das C; Dash SR; Bhal S; Pradhan R; Das B; Kundu CN
Med Oncol; 2024 Jan; 41(2):49. PubMed ID: 38184505
[TBL] [Abstract] [Full Text] [Related]
4. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract] [Full Text] [Related]
5. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy.
Zambelli A; Cazzaniga M; La Verde N; Munzone E; Antonazzo IC; Mantovani LG; Di Cosimo S; Mancuso A; Generali D; Cortesi PA
Breast; 2023 Oct; 71():113-121. PubMed ID: 37573652
[TBL] [Abstract] [Full Text] [Related]
6. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer.
Tolaney SM; Chan A; Petrakova K; Delaloge S; Campone M; Iwata H; Peddi PF; Kaufman PA; De Kermadec E; Liu Q; Cohen P; Paux G; Wang L; Ternès N; Boitier E; Im SA
J Clin Oncol; 2023 Aug; 41(24):4014-4024. PubMed ID: 37348019
[TBL] [Abstract] [Full Text] [Related]
7. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the treatment of cancer.
Toader D; Fessler SP; Collins SD; Conlon PR; Bollu R; Catcott KC; Chin CN; Dirksen A; Du B; Duvall JR; Higgins S; Kozytska MV; Bellovoda K; Faircloth C; Lee D; Li F; Qin L; Routhier C; Shaw P; Stevenson CA; Wang J; Wongthida P; Ter-Ovanesyan E; Ditty E; Bradley SP; Xu L; Yin M; Yurkovetskiy AV; Mosher R; Damelin M; Lowinger TB
Mol Cancer Ther; 2023 Sep; 22(9):999-1012. PubMed ID: 37294948
[TBL] [Abstract] [Full Text] [Related]
8. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Shih Y; Chen S; Huang J; Chen Y; Zhu Z; Zhao Q; Zhao X; Xue F; Xiang J; Chen X; Zhu X; Pan M; Wu J; Zheng J; Li H; Cao H
Rheumatology (Oxford); 2024 Jan; 63(1):251-258. PubMed ID: 37184873
[TBL] [Abstract] [Full Text] [Related]
9. Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients.
Wang B; Zhou M; Shi YY; Chen XL; Ren YX; Yang YZ; Tang LY; Ren ZF
Virchows Arch; 2023 Jun; 482(6):1047-1056. PubMed ID: 37059917
[TBL] [Abstract] [Full Text] [Related]
10. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
[TBL] [Abstract] [Full Text] [Related]
11. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Tung N; Armstrong A; Dymond M; Fielding A; Allen A; Conte P
Eur J Cancer; 2023 May; 184():39-47. PubMed ID: 36893711
[TBL] [Abstract] [Full Text] [Related]
12. PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast.
Zhi R; Wu K; Zhang J; Liu H; Niu C; Li S; Fu L
Cancer Sci; 2023 May; 114(5):1912-1928. PubMed ID: 36637351
[TBL] [Abstract] [Full Text] [Related]
13. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
Loibl S; Loirat D; Tolaney SM; Punie K; Oliveira M; Rugo HS; Bardia A; Hurvitz SA; Brufsky AM; Kalinsky K; Cortés J; O'Shaughnessy JA; Dieras V; Carey LA; Gianni L; Gharaibeh M; Preger L; Phan S; Chang L; Shi L; Piccart MJ
Eur J Cancer; 2023 Jan; 178():23-33. PubMed ID: 36379186
[TBL] [Abstract] [Full Text] [Related]
14. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract] [Full Text] [Related]
15. Quantitative Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative breast cancer Cells.
Ashrafian S; Zarrineh M; Jensen P; Nawrocki A; Rezadoost H; Ansari AM; Farahmand L; Ghassempour A; Larsen MR
J Proteome Res; 2022 Nov; 21(11):2566-2585. PubMed ID: 36173113
[TBL] [Abstract] [Full Text] [Related]
16. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (tpc) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).
Sim SH; Kim JE; Kim MH; Park YH; Kim JH; Suh KJ; Koh SJ; Park KH; Kang MJ; Ahn MS; Lee KE; Kim HJ; Ahn HK; Kim HJ; Park KU; Byun JH; Park JH; Lee GW; Lee KS; Sohn J; Jung KH; Park IH
Breast; 2022 Oct; 65():172-178. PubMed ID: 36029565
[TBL] [Abstract] [Full Text] [Related]
17. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
18. The response of the canine mammary simple carcinoma and carcinosarcoma cells to 5-aminolaevulinic acid-based photodynamic therapy: An in vitro study.
Eskiler GG; Turna O; Ozkan AD; Baykal A; Gurgen HO; Erk B; Armutak EI; Lim HS
J Photochem Photobiol B; 2022 Sep; 234():112509. PubMed ID: 35810598
[TBL] [Abstract] [Full Text] [Related]
19. Silencing of B7-H4 induces intracellular oxidative stress and inhibits cell viability of breast cancer cells via downregulating PRDX3.
Chen HC; Long M; Gao ZW; Liu C; Wu XN; Yang L; Dong K; Zhang HZ
Neoplasma; 2022 Jul; 69(4):940-947. PubMed ID: 35723197
[TBL] [Abstract] [Full Text] [Related]
20. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
Ohno K; Shibata T; Ito KI
Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
[TBL] [Abstract] [Full Text] [Related]
[Next]
